Surgeons Complete First Procedures Across the U.S. Utilizing Medtronic's Midas Rex Drills and Navigated Disc Prep and Interbodies with the Mazor Robotic Guidance System

Dr. Gregory Poulter of OrthoIndy , Dr. Sharad Rajpal of Boulder Neurosurgical & Spine Associates and Dr. Eiman Shafa of Twin Cities Spine Center Are First in the U.S. to Complete Surgeries Using the Most Comprehensive Integrated Spine Surgery Platform Available

- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that leading spine surgeons across the U.S. have successfully performed minimally invasive spinal procedures utilizing the newly cleared navigated disc prep, interbodies and Midas Rex™ high speed drills with the Mazor™ Robotic Guidance System. These recent surgeries mark the next step in the transformation of spine surgery as a result of the increased precision and minimally invasive technique.

These cases demonstrated the improved disc-prep access and interbody navigation, precise drilling, and predictable planning that surgeons expect from the Mazor Robotic Guidance System.

  • Dr. Gregory Poulter of OrthoIndy: Performed his first case on a 50-year-old male, a general manager at a construction company who presented with a pinched nerve in his lower back and severe leg pain. Dr. Poulter was able to conduct an OLIF360 sm Single Position Surgery and discharge the patient the following day.
  • Dr. Sharad Rajpal of Boulder Neurosurgical & Spine Associates: Conducted his first surgery at Centura-Avista Adventist Hospital using the integrated technology on an 83-year-old male, retired atmospheric physicist suffering from back and severe progressive leg pain and weakness that prevented him from walking. Dr. Rajpal performed an L2/3 decompression fusion and TLIF (Transforaminal Lumbar Interbody Fusion) on the patient, who has been discharged from the hospital and is home recovering with minimal pain and improved functionally.
  • Dr. Eiman Shafa of Twin Cities Spine Center: Completed his first minimally invasive TLIF with bilateral instrumentation using expandable interbody technology on a 36-year-old male, boiler operator/maintenance technician with back and severe left lower extremity pain and progressive weakness. The patient was observed overnight and discharged the morning after his surgery. The morning post-surgery, the patient's radicular leg pain and motor examination had returned to normal.

"Robotic assistance has fundamentally changed how we as spinal surgeons operate," said Dr. Poulter. "I believe in the benefits of robotics such that I would strongly recommend it to all of my friends or family if they are in need of a lumbar spine procedure, as I see this as potentially life-changing."

Despite elective surgery shutdowns due to the COVID-19 pandemic, many spinal procedures have continued, deemed essential due to the severity of the patient's disability.

"I believe this technology allows surgeons to perform their spinal procedures even better through more concise planning and execution in the operating room," said Dr. Rajpal. "One additional advantage is the versatility of the system. Surgeons can easily integrate the Mazor Robotic Guidance System into their current workflows - whether it's using a pre-operative planning CT with intraoperative fluoroscopy or using an O-arm™ for scanning and planning altogether in the operating room. The newest software update and instrumentation sets have also significantly improved the workflow, providing a more intuitive interface for surgeons during the planning phase, to more streamlined steps when executing the surgical plan."

"We want to congratulate each of these surgeons – and their patients – on successful procedures and recoveries," said Linnea Burman , vice president and general manager, Enabling Technologies: Cranial & Spinal Technologies, which is reported as part of the Restorative Therapies Group at Medtronic. "We continuously strive to improve the robotic surgery field, and hearing about these great success stories and how these patients' lives have been affected gives our team more motivation to achieve the next level of advancement."

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:




David T. Young

Ryan Weispfenning

Public Relations

Investor Relations

+1-774-284-2746

+1-763-505-4626

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/surgeons-complete-first-procedures-across-the-us-utilizing-medtronics-midas-rex-drills-and-navigated-disc-prep-and-interbodies-with-the-mazor-robotic-guidance-system-301228645.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Americans favor quality over quantity in pursuit of longevity

According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they'd opt for a shorter, healthier life than a longer one with health issues

Americans overwhelmingly say that when they think about longevity, it's more than just living longer—it's about living their healthiest, best lives. While most want to live to 90—well past the average U.S. life expectancy of 77.5 years—nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live healthier years and the opportunity for more people to improve their quality of life through healthcare technology.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% ww), is now available to patients through BC PharmaCare, the public drug program of British Columbia

ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Keep reading...Show less

Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×